Cost-Utility Analysis of Nivolumab in the Adjuvant Treatment of Melanoma in France
media
posted on 2020-09-11, 15:40 authored by Bruno Bregman, Siguroli Teitsson, Isabella Orsini, François-Emery Cotté, Adenike Amadi, Andriy Moshyk, Stéphane Roze, Anne-Françoise Gaudin<p>The above summary slide represents
the opinions of the authors. For a full list of declarations, including funding
and author disclosure statements, please see the full text online (see “read
the peer-reviewed publication” opposite).<br></p>
<p>© The authors, CC-BY-NC 2020.</p>
<p> </p>
History
Related Materials
- 1.
- 2. DOI - Is supplement to Cost-Utility Analysis of Nivolumab in the Adjuvant Treatment of Melanoma in France
